The FDA has approved capivasertib (Truqap) in combination with abiraterone acetate (Zytiga) and prednisone for adults with ...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
First PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‑altered metastatic hormone‑sensitive prostate cancer, including both BRCA and non‑BRCA alterations There was an ...
The advent of more effective treatment combinations for metastatic hormone-sensitive prostate cancer (mHSPC) has been built on successes in therapy development for metastatic, castration-resistant ...
A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...
Hosted on MSN
Expert Q&A: The Link Between Fatigue and Advanced Prostate Cancer — Plus Tips to Manage It
Many people with prostate cancer experience fatigue as a symptom of the cancer and as a side effect of treatment. In fact, up to 90 percent of men with prostate cancer experience fatigue.
NPR's Ayesha Rascoe talks with urologist Ben Davies about the prevalence of prostate cancer, new treatments, and patients' reluctance to discuss the disease and its aftermath. Early last week, after ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results